Table 1.
ICI monotherapy for BRAF-mutated NSCLC.
| Trial | Mutation type | Numbers | objective response rate (ORR) | progression free survival (PFS) | overall survival (OS) |
|---|---|---|---|---|---|
| Immunotarget | V600E | 17 | NA | 1.8 | 8.2 |
| Non-V600E | 18 | NA | 4.1 | 17.2 | |
| Memorial Sloan Kettering Cancer center (MSKCC) | V600E | 10 | 10 | 1.4 | 26 |
| Non-V600E | 36 | 22 | 3.2 | 24 | |
| Isarel lung cancer group (ICLG) | V600E | 12 | 25 | 3.7 | NA |
| Non-V600E | 10 | 33 | 4.1 | ||
| Expanded Access Program (EAP) Nivolumab | BRAF | 11 | 9 | NA | 10.3 |
| French Lung Cancer Group (GFPC) 01-2018 | V600E | 26 | 26 | 5.3 | 22.5 |
| Non-V600E | 18 | 35 | 4.9 | 12 |